Sarosy G - Search Results

1

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, et al. Kohn EC, et al. Among authors: sarosy g. J Natl Cancer Inst. 1994 Jan 5;86(1):18-24. doi: 10.1093/jnci/86.1.18. J Natl Cancer Inst. 1994. PMID: 7505830 Clinical Trial.

2

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A, Minasian L, Reed E, Steinberg SM, Kohn EC. Sarosy GA, et al. Cancer. 2010 Mar 15;116(6):1476-84. doi: 10.1002/cncr.24861. Cancer. 2010. PMID: 20091841 Free PMC article. Clinical Trial.

3

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.

Link CJ Jr, Bicher A, Kohn EC, Christian MC, Davis PA, Adamo DO, Reed E, Sarosy GA. Link CJ Jr, et al. Among authors: sarosy ga. Blood. 1994 Mar 1;83(5):1188-92. Blood. 1994. PMID: 7509652 Free article. Clinical Trial.

4

Incapacitating autonomic neuropathy precipitated by taxol.

Jerian SM, Sarosy GA, Link CJ Jr, Fingert HJ, Reed E, Kohn EC. Jerian SM, et al. Among authors: sarosy ga. Gynecol Oncol. 1993 Nov;51(2):277-80. doi: 10.1006/gyno.1993.1287. Gynecol Oncol. 1993. PMID: 7903950

5

Cutaneous manifestations of Taxol therapy.

Link CJ Jr, Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, Reed E. Link CJ Jr, et al. Among authors: sarosy ga. Invest New Drugs. 1995;13(3):261-3. doi: 10.1007/BF00873811. Invest New Drugs. 1995. PMID: 8729957

6

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.

Kohn EC, Sarosy GA, Davis P, Christian M, Link CE, Ognibene FP, Sindelar WF, Jacob J, Steinberg SM, Premkumar A, Reed E. Kohn EC, et al. Among authors: sarosy ga. Gynecol Oncol. 1996 Aug;62(2):181-91. doi: 10.1006/gyno.1996.0213. Gynecol Oncol. 1996. PMID: 8751547 Clinical Trial.

7

Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.

Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC. Shapiro JD, et al. Among authors: sarosy ga. Cancer. 1998 Nov 1;83(9):1980-8. Cancer. 1998. PMID: 9806657 Clinical Trial.

8

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E. Sarosy G, et al. J Clin Oncol. 1992 Jul;10(7):1165-70. doi: 10.1200/JCO.1992.10.7.1165. J Clin Oncol. 1992. PMID: 1376773 Clinical Trial.

9

Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.

Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M. Reed E, et al. Among authors: sarosy g. Semin Oncol. 1995 Jun;22(3 Suppl 6):90-6. Semin Oncol. 1995. PMID: 7541159 Review.

10

Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.

Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner BA, Reed E. Bicher A, et al. Among authors: sarosy g. Cancer. 1993 Jan 15;71(2 Suppl):594-600. doi: 10.1002/cncr.2820710216. Cancer. 1993. PMID: 7678382 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page